What is the classification of Nitrofurantoin (antibiotic)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 7, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Nitrofurantoin Drug Classification

Nitrofurantoin is a synthetic nitrofuran antibiotic with broad-spectrum bactericidal activity against both Gram-positive and Gram-negative uropathogens. 1, 2

Pharmacological Class

  • Nitrofurantoin belongs to the nitrofuran class of antimicrobials, a unique category of synthetic antibiotics that have been in clinical use since 1953 1, 2
  • It is classified as a broad-spectrum bactericidal antibiotic with activity specifically concentrated in urinary tract tissues 2, 3

Mechanism of Action

  • Nitrofurantoin interferes with multiple bacterial targets through a complex mechanism that is not completely understood 2
  • It affects bacterial cell wall synthesis, protein synthesis, and DNA replication in both Gram-positive and Gram-negative organisms 3
  • This multi-target mechanism contributes to its low propensity for resistance development 1, 2

Antimicrobial Spectrum

  • Active against common uropathogens including E. coli, Klebsiella species, Enterobacter species, Enterococcus species (including VRE), and Staphylococcus aureus 3, 4
  • Maintains activity against multidrug-resistant organisms, making it valuable in the current era of antimicrobial resistance 2, 3
  • Not effective against Pseudomonas species or for systemic infections due to poor tissue penetration outside the urinary tract 5

Regulatory Classification

  • WHO AWaRe Classification: Access Group antibiotic for uncomplicated urinary tract infections 4
  • FDA-approved since the 1950s specifically for treatment of lower urinary tract infections 4
  • Categorized as a first-line agent for uncomplicated cystitis in multiple international guidelines 4

Clinical Positioning

  • Recommended as first-choice therapy for uncomplicated lower UTIs by IDSA/ESMID guidelines alongside trimethoprim-sulfamethoxazole and fosfomycin 4
  • Preferred over fluoroquinolones for empiric treatment to preserve broader-spectrum agents and minimize resistance 4
  • Should only be used for lower urinary tract infections, not for pyelonephritis or systemic infections due to inadequate tissue concentrations 5, 4

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.